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Although integrin ␣ subunit I domains exist in multiple conformations, it is controversial whether integrin ␤
subunit I-like domains undergo structurally analogous
movements of the ␣7-helix that are linked to affinity for
ligand. Disulfide bonds were introduced into the ␤3 integrin I-like domain to lock its ␤6-␣7 loop and ␣7-helix in
two distinct conformations. Soluble ligand binding, ligand mimetic mAb binding and cell adhesion studies
showed that disulfide-bonded receptor ␣IIb␤3T329C/A347C
was locked in a low affinity state, and dithiothreitol
treatment restored the capability of being activated to
high affinity binding; by contrast, disulfide-bonded
␣IIb␤3V332C/M335C was locked in a high affinity state. The
results suggest that activation of the ␤ subunit I-like
domain is analogous to that of the ␣ subunit I domain,
i.e. that axial movement in the C-terminal direction of
the ␣7-helix is linked to rearrangement of the I-like domain metal ion-dependent adhesion site into a high affinity conformation.

Integrins are large heterodimeric adhesion molecules that
convey signals bidirectionally across the plasma membrane (1,
2). Both integrin subunits are type I transmembrane proteins
with large extracellular domains. Priming of the extracellular
domain for ligand binding (i.e. increasing its affinity for ligand)
is initiated by moving apart the ␣ and ␤ subunit cytoplasmic
domains and probably separation of the transmembrane domains as well (3). Conversely, binding of ligand can also initiate cytoplasmic domain separation (3); the equilibria relating
conformational change and ligand binding are linked (4). The
low affinity integrin conformation is highly bent, with the
headpiece that contains the ligand binding domains in an extensive interface with the tailpiece that contains the ␣ and ␤
subunit legs (4 – 8) (Fig. 1A). After priming or ligand binding, a
switchblade-like opening extends the headpiece away from the
membrane (4, 7) (Fig. 1, B and C). In extended integrins, two
conformations of the headpiece are seen. The open conformation of the headpiece (Fig. 1C) is present when ligand is bound
and differs from the closed conformation (Fig. 1B) in the presence of an obtuse angle between the ␤-subunit hybrid and I-like
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domains (4, 8). Recently, we mutationally introduced N-glycosylation sites into the interface of the hybrid and I-like domains
to stabilize the open headpiece. The wedged-open mutants exhibited constitutively high affinity for ligand and adopted an
extended conformation (9).
We have proposed that the change in affinity at the ligand
binding site in the I-like domain around its metal ion-dependent adhesion site (MIDAS)1 is communicated to the interface
with the hybrid domain on the opposite end of the I-like domain
by axial displacement in the C-terminal direction of the I-like
domain ␣7-helix (4, 8, 9) (Fig. 1, B and C). The ␤-subunit I-like
domain is inserted in the hybrid domain, and thus these domains have two interconnections. A piston-like movement at
the I-like ␣7-helix connection and pivoting about the other
connection would yield a swing at the I-like-hybrid domain
interface approximating that seen in electron microscopy studies (4, 8). One basis for proposing this mechanism for communicating a change in affinity to the I-like domain MIDAS is that
the structurally homologous I domain inserted in some integrin
␣ subunits undergoes a similar piston-like movement of its
C-terminal ␣7-helix, which regulates the affinity of its MIDAS
for ligand (2).
There is controversy concerning this proposed mechanism.
Soaking of a ligand-mimetic Arg-Gly-Asp (RGD) peptide into
integrin ␣V␤3 crystals, in which ␣V␤3 was constrained in the
bent conformation by lattice contacts, induced ␤6-␣7 loop and
␣1-helix movements, but not ␣7-helix displacement (5). It was
therefore suggested that ␣ I and ␤ I-like domains are activated
by distinct mechanisms. Demonstration of movement of an
epitope in the ␣1-helix was used to support the hypothesis that
the mechanism of I-like domain activation differs from that of
the I domain (10). On the other hand, conformational change at
this region would not contradict C-terminal ␣7-helix movement, and the mutation L358A in the ␣7-helix of the ␤1 I-like
domain causes activation, supporting some type of conformational change around the ␣7-helix upon ligand binding (11).
Furthermore, solution x-ray scattering studies and exposure of
epitopes on the inner side of the hybrid domain in the presence
of ligand (11, 12) support the direct observations of hybrid
domain swing-out (4, 8).
Here, we directly test the hypothesis that specific rearrangements occur in the ␤6-␣7 loop and ␣7-helix of ␤ I-like domains
that are structurally analogous to those that occur in ␣ I
domains and are linked to integrin activation. Disulfide bonds
have previously been introduced into ␣ I domains to constrain

1
The abbreviations used are: MIDAS, metal ion-dependent adhesion
site; TBS, Tris-buffered saline; DTT, dithiothreitol; biotin-BMCC, 1-biotinamido-4 (4⬘-[maleimodoethyl-cyclohexane]-carboxamido)butane;
FITC, fluorescein isothiocyanate; HBS, Hepes-buffered saline; BSA,
bovine serum albumin; mAb, monoclonal antibody; CHO, Chinese hamster ovary.
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the ␤6-␣7 loop and ␣7-helix. The ␣L (13–16) and ␣M (17) I
domains have been locked into closed, intermediate, or open
conformers with low, intermediate, or high affinity for ligand,
respectively. Crystal structure studies on the mutant ␣L I domains confirmed alterations in the ␤6-␣7 loop corresponding to
␣7-helix displacements of one and two turns of helix in the
intermediate and open conformations, respectively (16). The
disulfide-constrained, high affinity, open conformation of
the ␣L I domain corresponds precisely in the critical ␤6-␣7 loop
and MIDAS loops to the open conformation of the wild-type ␣2
and ␣M I domains seen when this conformation was stabilized
in crystals by ligand or ligand-like lattice contacts (18, 19). The
studies reported here on the ␤ I-like domain show that disulfide
bonds mutationally introduced into the ␤6/␣7 region lock integrins that lack I domains into two distinct affinity states. The
data uniquely support the proposal that downward movement
of the ␣7-helix induces I-like domain activation and demonstrate that ␣ I and ␤ I-like domains are activated by structurally analogous mechanisms.
MATERIALS AND METHODS

High Affinity I-like Domain Model—The model was built with the
Segmod module (20) of GeneMine version 3.5 using residues 108 –333
and 347–353 of Protein Data Bank accession number 1JV2 (6) as
template and aligning them with residues 108 –333 and 340 –346 of the
model sequence, respectively. This corresponded to a 7-residue, 2-turn
displacement of the ␣7-helix along its helical axis; residues 334 –339
were left nontemplated.
Plasmid Construction, Transient Transfection, and Immunoprecipitation—Plasmids coding for full-length human ␣IIb and ␤3 were subcloned into pEF/V5-HisA or pcDNA3.1/Myc-His(⫹) as described previously (4). Mutants were made using site-directed mutagenesis with the
QuikChange kit (Stratagene, La Jolla, CA), and DNA sequences were
confirmed before being transfected into 293T cells using calcium phosphate precipitates (21). Transfected cells were metabolically labeled
with [35S]cysteine/methionine as described (4). Lysates in 20 mM Trisbuffered saline, pH 7.4 (TBS), supplemented with 1 mM Ca2⫹, 1 mM
Mg2⫹, 1% Triton X-100, and 0.1% Nonidet P-40 were immunoprecipitated with 1 g of anti-␤3 mAb AP3 and protein G-Sepharose at 4 °C for
1 h and subjected to nonreducing SDS 7.5% PAGE and fluorography
(22).
Labeling of Free Cysteines and Western Blotting—Transiently transfected 293T cells, treated with or without 5 mM DTT at 37 °C for 30 min
in TBS containing 1 mM Ca2⫹, followed by washing with TBS plus 1 mM
Ca2⫹ three times, were labeled with 400 M 1-biotinamido-4 (4⬘-[maleimodoethyl-cyclohexane]-carboxamido)butane (biotin-BMCC) (Pierce)
at room temperature for 30 min, washed with TBS plus 1 mM Ca2⫹
three times, and lysed with TBS with 1% Triton X-100 and 0.1%
Nonidet P-40. ␣IIb␤3 was immunoprecipitated with AP3 mAb-Sepharose
at 4 °C for 1 h and subjected to SDS 7.5% PAGE. Samples were transferred to polyvinylidene difluoride membranes and probed with 2 g/ml
horseradish peroxidase-conjugated avidin at 20 °C for 30 min or with 2
g/ml anti-myc antibody (Invitrogen) for 30 min at 20 °C, followed by
washing and 2 g/ml horseradish peroxidase-conjugated anti-mouseIgG (Zymed Laboratories Inc., San Francisco, CA) for 30 min at 20 °C,
and then detected by chemiluminescence using the ECL Western blotting kit (Amersham Biosciences). BioMax film (Eastman Kodak Co.)
was exposed for about 20 s. The film was scanned using DUOSCAN
1200 (Agfa, Mortsel, Belgium), and data were saved as a tiff file. NIH
Image 1.62 (NIMH, National Institutes of Health, Bethesda, MD) was
used to determine the intensity of each band within identical rectangular areas. After subtracting the intensity of mock transfectants in the
same areas, the ratio of the intensity of BMCC and myc bands was
determined.
Two-color Ligand Binding Assay on 293T Transfectants—Binding of
FITC-labeled human fibrinogen was determined as described (4).
Briefly, transiently transfected 293T cells in 20 mM Hepes-buffered
saline (pH 7.4) (HBS) supplemented with 5.5 mM glucose and 1% BSA
were incubated with 60 g/ml fluorescein-labeled fibrinogen in the
presence of 1 mM EDTA, 5 mM Ca2⫹, or 1 mM Ca2⫹ plus 10 g/ml PT25-2
mAb at 20 °C for 30 min, and then 10 g/ml Cy3-labeled mAb AP3 was
added, and cells were incubated on ice for another 30 min before being
subjected to flow cytometry. Fibrinogen binding was expressed as a
percentage of the mean fluorescence intensity of FITC-fibrinogen relative to that of staining with AP3 mAb.

Expression and Ligand Binding Activity of ␣IIb␤3 on CHO-K1 Transfectants—The plasmids described above coding for ␣IIb and ␤3 were
introduced into CHO-K1 cells using calcium phosphate precipitates
(21). Transfectants were selected with 5 mg/ml G418. After 2 weeks, the
cells were stained with AP3 mAb and subjected to fluorescence-activated cell sorting to obtain lines expressing the desired level of ␣IIb␤3.
Prior to ligand binding, transfected cells were suspended in HBS supplemented with 5.5 mM glucose and 1% BSA and incubated with 1 mM
EDTA, 5 mM Ca2⫹, or 1 mM Ca2⫹ plus 10 g/ml PT25-2, with or without
5 mM DTT, at 20 °C for 30 min. Staining with fluorescein-labeled
human fibrinogen and the ligand mimetic PAC-1 mAb (Becton Dickinson, San Jose, CA) was measured as described (4).
Cell Adhesion to Immobilized Fibrinogen—Cell adhesion was assayed as described (23). Briefly, transfected CHO-K1 cells were labeled
with 2⬘,7⬘-bis-(carboxyethyl)-5(and-6)-carboxyfluorescein (Molecular
Probes, Inc., Eugene, OR) and suspended to 106/ml in HBS supplemented with 5.5 mM glucose, 1% BSA, and either 1 mM EDTA, 5 mM
Ca2⫹, or 5 mM DTT plus 5 mM Ca2⫹. Cell suspensions were incubated in
wells that had been coated with different concentrations of fibrinogen
followed by blocking with 1% BSA. After incubation at 37 °C for 1 h,
unbound cells were washed off after three resuspensions with a multichannel pipette. The fluorescence of input cells and bound cells in each
well was quantitated on a fluorescent concentration analyzer (Idexx,
Westbrook, ME). Bound cells were expressed as a percentage of total
input cells.
LIBS Expression—Anti-LIBS mAbs LIBS-1, LIBS-6, and PMI-1 were
kind gifts of M. H. Ginsberg (Scripps Research Institute, La Jolla, CA).
LIBS expression was measured as described (9). In brief, CHO-K1 cells
stably expressing wild type or mutant ␣IIb␤3 in HBS supplemented with
5.5 mM glucose and 1% BSA were incubated under different conditions
as indicated in the legend to Fig. 5 for 30 min at 20 °C. LIBS mAbs were
added to a final concentration of 10 g/ml, and cells were incubated on
ice for another 30 min before staining with FITC-conjugated anti-mouse
IgG and flow cytometry.
RESULTS

Design of I-like Domains Locked in Low Affinity and High
Affinity Conformations—We hypothesized that in both the unliganded and liganded ␣V␤3 structures (5, 6), the C-terminal
␣7-helix of the ␤3 I-like domain is in a position stabilizing a
closed, low affinity conformation; therefore, these structures
were used to design low affinity mutants. An open, high affinity
conformation was modeled assuming that the ␣7-helix was
displaced in the C-terminal axial direction by two ␣-helical
turns (see “Materials and Methods”). The distance between C␤
atoms of Thr329 and Ala347 in the unliganded and RGD-liganded ␣V␤3 structures is 4.4 and 4.9 Å, respectively, whereas it is
9.6 Å in the hypothesized high affinity model. Therefore, the
mutant ␤3T329C/A347C was expected to form a disulfide bond in
the low but not the high affinity conformation and to be stabilized in the low affinity, closed conformation (Fig. 1, D and F).
On the other hand, the distance between the C␤ atoms of Val332
and Met335 in the unliganded and RGD-liganded ␣V␤3 structures is 10.0 and 8.3 Å, respectively, whereas it is 3.7 Å in the
hypothesized high affinity model. Therefore, the mutant
␤3V332C/M335C was expected to form a disulfide bond in the high
but not the low affinity conformation (Fig. 1, E and G) and to be
stabilized in the high affinity, open conformation.
Expression of Wild Type and Mutant ␣IIb␤3 Receptors and
Formation of Disulfide Bonds—Wild type and mutant ␤3 subunits were co-transfected with wild type ␣IIb in 293T cells and
subjected to immunostaining flow cytometry (Fig. 2, A and B).
The wild type and mutant receptors were recognized equally
well by mAb to epitopes constitutively present on the ␣IIb and
␤3 subunits, including AP3 (anti-␤3), 10E5 (anti-␣IIb), HA5
(anti-␣IIb), and AP2 (anti-␣IIb␤3 complex-specific) (Fig. 2A),
suggesting that the two mutant receptors adopted a native fold
on the cell surface. However, the mutant ␤3V332C/M335C receptor
was recognized weakly by anti-␤3 mAb 7E3 (Fig. 2B). The 7E3
mAb recognizes residues in the specificity-determining, ␤2-␤3
loop near the ␤3 I-like MIDAS (24). Since the single cysteine
mutants ␤3V332C and ␤3M335C were recognized by 7E3 (Fig. 2B),
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FIG. 1. Model of integrin activation and design of mutant ␤3
I-like domains. A–C, model for integrin activation, with at least three
conformations of the extracellular domain (4). A, bent, low affinity
conformation. B, extended conformation with closed headpiece. C, extended conformation with open headpiece. The outward swing of the
hybrid domain is hypothesized to result from downward movement of
the I-like domain ␣7-helix (yellow cylinder) and pivoting about the other
␤ I-like-hybrid domain connection at about residue 106 (black circle).
D–G, design of mutants of the ␤3 I-like domain. For clarity, only two
segments of the I-like domain, from the ␤1-␣1 loop to the ␣1-helix and
from the ␤5-strand to the ␣7-helix are shown. Cysteine substitutions
(yellow stick and ball) were modeled with SwissPdb Viewer (28). The
MIDAS metal ion (silver sphere) (5) is added to identify the ligand
binding site. D, low affinity structure with T329C/A347C mutation. E,
low affinity structure with V332C/M335 mutation. F, high affinity
model with T329C/A347C mutation. G, high affinity model with V332C/
M335C mutation. The low affinity structure is from IJV2; the high
affinity model is described under “Materials and Methods.” This figure
was prepared with RIBBONS (29).

the conformational change induced by the disulfide bond
formed between V332C and M335C (see below) appears to
diminish the 7E3 epitope. By contrast, mutant ␤3T329C/A347C
was well recognized by 7E3 (data not shown) (see Fig. 4A).
Nonreducing SDS-PAGE of 35S-labeled, immunoprecipitated
receptors showed that the ␣IIb subunits migrated similarly
(Fig. 2C), whereas the mutant ␤3T329C/A347C and ␤3V332C/M335C
subunits (Fig. 2C, lanes 6 and 7) migrated slightly faster than
wild type ␤3 (Fig. 2C, lane 5). By contrast, all ␤3 single cysteine
mutants migrated similarly to wild-type ␤3 (Fig. 2C, lanes 1– 4).
In general, disulfide bonds increase the mobility of proteins in
SDS-PAGE, and these results suggest that the cysteines introduced into the ␤3T329C/A347C and ␤3V332C/M335C mutants form a
disulfide bond.
To confirm disulfide bond formation, free sulfhydryls were
labeled with the maleimide-containing reagent, biotin-BMCC.
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FIG. 2. Expression of mutant ␣IIb␤3 integrins on 293T cells and
formation of disulfide bonds. A and B, immunofluorescent flow
cytometry. A, 293T transfectants were labeled with AP3 (anti-␤3), 10E5
(anti-␣IIb), HA5 (anti-␣IIb), and AP2 (anti-␣IIb␤3 complex-specific). Thick
and thin lines show labeling of the ␣IIb␤3 transfectant and the mock
transfectant, respectively. B, labeling with 7E3 mAb (thick line) or X63
control IgG1 (thin line). C, immunoprecipitation. Lysates from 35Slabeled 293T cell transfectants were immunoprecipitated with mAb
AP3. Precipitates were subjected to nonreducing SDS-7.5% PAGE and
fluorography. Segments of straight lines drawn through the ␤3 bands in
lanes 1–5 and lanes 6 and 7 are shown between lanes to emphasize the
difference in migration. D, labeling of free cysteines. Transfected cells
were treated with (wild-type only) or without 5 mM DTT at 37 °C for 30
min and labeled with biotin-BMCC at room temperature for 30 min.
Immunoprecipitates with AP3 mAb-Sepharose were subjected to nonreducing 7.5% SDS-PAGE. Western blotting was with HRP-avidin to
detect biotin-BMCC or anti-myc mAb to detect the myc-tagged ␤3
subunit.

The idea was that introducing a single cysteine should increase
labeling, whereas introducing two cysteines would not increase
labeling if they formed a disulfide bond. Transfectants were
treated with biotin-BMCC, lysed, immunoprecipitated with
AP3 mAb to ␣IIb␤3, and subjected to SDS-PAGE and blotting
with avidin (Fig. 2D). The ␤3 subunit was fused at its C terminus to a myc tag, and blotting with a myc mAb was used as a
control for ␤3 loading. Whereas wild-type ␣IIb␤3 showed almost
no biotin labeling (Fig. 2D, lane 2), the ␣IIb␤3 single cysteine
mutants V332C and M335C showed marked labeling (Fig. 2D,
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FIG. 3. Ligand binding activity of mutant ␣IIb␤3 integrins on
293T cells. A, soluble fibrinogen binding of 293T cell transfectants in
the presence of 5 mM Ca2⫹ (white bar) or 1 mM Ca2⫹ plus 10 g/ml
PT25-2 (black bar) at room temperature for 30 min. B, effect of mAbs.
Soluble fibrinogen binding in the presence of 5 mM Ca2⫹ was measured
in presence of activating LIBS antibody AP5 or blocking antibodies HA5
and 10E5. The control is with X63 IgG1. Fibrinogen binding was measured with two-color immunofluorescence as described under “Materials
and Methods” and is expressed as the mean fluorescence intensity of
fibrinogen staining as a percentage of mean fluorescence intensity of
staining with AP3 mAb.

lanes 4 and 6). The cysteines introduced in the V332C/M335C
and T329C/A347C mutants clearly formed disulfides, because
labeling was at the same level as the wild type (Fig. 2D, lanes
5 and 7), whereas it would have been twice that of the single
cysteine mutants if disulfides had not formed. To estimate the
number of free cysteines per ␤3 subunit, the ratio of the intensity of avidin binding to that of anti-myc binding was determined. As an additional control, wild-type ␣IIb␤3 on the transfectants was treated with 5 mM DTT for 30 min at 37 °C. The
avidin/anti-myc ratios for the wild type, wild type with DTT
treatment, ␤3V332C, ␤3V332C/M335C, ␤3M335C, and ␤3T329C/A347C
subunits were 0.05, 0.82, 0.20, 0.04, 0.19, and 0.04, respectively. If ␤3V332C is assumed to have one additional free cysteine sulfhydryl compared with wild type, then ␤3M335C also
has 1.0 additional free cysteine, ␤3V332C/M335C and ␤3T329C/A347
have no additional free ␤3 cysteines, and wild type ␣IIb␤3
treated with DTT has 5.2 free cysteines. By contrast, there are
a total of 54 cysteines in wild type ␤3.
Ligand Binding Properties of 293T Transfectants with Disulfide-locked Receptors—Binding to soluble fibrinogen was first
examined using two-color flow cytometry (4) in transiently transfected 293T cells, in which wild type ␣IIb␤3 basally has low
affinity for ligand. Wild type ␣IIb␤3 bound fibrinogen when stimulated with the activating mAb PT25-2 but not basally in Ca2⫹
(Fig. 3A). Each of the four single cysteine mutants behaved similarly to the wild type receptor (Fig. 3A). By contrast, the
putative locked closed, double cysteine mutant ␣IIb␤3T329C/A347C
did not bind soluble fibrinogen even in the presence of PT25-2
(Fig. 3A). Furthermore, the putative locked open mutant
␣IIb␤3V332C/M335C bound soluble fibrinogen even in Ca2⫹, and
the addition of PT25-2 mAb did not further increase binding
(Fig. 3A). Constitutive binding in Ca2⫹ by the ␣IIb␤3V332C/M335C
mutant was abolished by two blocking ␣IIb mAbs, HA5 and
10E5, but neither blocked nor further activated by the activat-

ing ␤3 mAb AP5 (Fig. 3B), confirming that the high affinity
binding of the transfected cells was specific.
Functional Properties of Mutant Receptors in CHO-K1 Transfectants—To further examine the disulfide-locked receptors,
stable CHO-K1 transfectants were established, and clones
were selected that expressed similar quantities of wild-type
␣IIb␤3, ␣IIb␤3T329C/A347C, and ␣IIb␤3V332C/M335C. The transfectants were recognized equally well by a panel of mAb to constitutively expressed ␣IIb, ␤3, and ␣IIb␤3 epitopes, with the
exception of 7E3 mAb (Fig. 4A). Mutant ␣IIb␤3V332C/M335C
blunted but did not completely abolish the binding of 7E3.
CHO-K1 transfectants expressing the wild type receptor did
not bind soluble fibrinogen or PAC-1 in Ca2⫹ but bound when
stimulated by activating mAb PT25-2 (Fig. 4, B and C). Treatment with 5 mM DTT at 20 °C for 30 min slightly increased
ligand binding to wild type ␣IIb␤3 in Ca2⫹, but this binding was
much less than that seen with PT25-2 mAb with or without
DTT treatment. Mutant ␣IIb␤3T329C/A347C did not bind fibrinogen or PAC-1 basally, and binding was not stimulatable with
PT25-2. However, DTT treatment restored the ability of
PT25-2 to stimulate fibrinogen and PAC-1 binding (Fig. 4, B
and C), suggesting that the Cys329–Cys347 disulfide bond
locked the I-like domain in the closed conformation, and this
constraint was released by DTT treatment. By contrast, mutant ␣IIb␤3V332C/M335C showed high binding to soluble fibrinogen and PAC-1, and binding was not further increased by
activation. DTT treatment did not reduce fibrinogen or PAC-1
binding of the ␣IIb␤3V332C/M335C mutant in Ca2⫹, probably because the Cys332–Cys335 disulfide bond was stable to reduction
under nondenaturing conditions like the vast majority of the
native disulfides in ␤3.
The affinity state of disulfide-bonded mutants was further
tested in cell adhesion assays on immobilized fibrinogen. High
affinity is required for binding to soluble ligand or ligand mimetic mAbs. In contrast, wild type ␣IIb␤3 can mediate cell
adhesion to immobilized fibrinogen in the absence of activation,
as long as high coating concentrations above 1 g/ml of fibrinogen are used (Fig. 4D), consistent with our previous report (9).
DTT treatment slightly increased the avidity of the wild type
receptor, as shown by a shift in the dose-response curve. In
contrast, mutant ␣IIb␤3T329C/A347C did not adhere even at the
highest coating concentration of fibrinogen, whereas DTT
treatment yielded binding of ␣IIb␤3T329C/A347C indistinguishable from that of the DTT-treated wild type receptor, suggesting that DTT treatment could release the disulfide bond, which
locked the receptor in the low avidity state. On the other hand,
the high affinity ␣IIb␤3V332C/M335C mutant adhered to immobilized fibrinogen at coating concentrations as low as 0.3 g/ml,
and DTT treatment did not alter its binding avidity, consistent
with the results for soluble ligand binding.
Ligand-induced Binding Site (LIBS) Epitope Expression—
Priming and ligand binding alter the conformation of ␣IIb␤3,
resulting in the exposure of so-called LIBS. Such epitopes are
buried in the bent conformation in interfaces between the headpiece and tailpiece and between the ␣ leg and ␤ leg and are
exposed in the extended conformation (4, 7). To probe the
conformational state of the ␣IIb␤3 mutants, binding of a panel
of anti-LIBS mAbs was determined. The mAbs LIBS1 (anti-␤3;
residues 420 – 690), LIBS6 (anti-␤3; residues 602– 690), and
PMI-1 (anti-␣IIb; residues 844 – 859) bound poorly to the cells
stably expressing wild-type ␣IIb␤3 in Ca2⫹ but bound maximally to ␣IIb␤3 activated with Mn2⫹ and RGD peptide (Fig. 5).
DTT treatment for 30 min at 20 °C increased to different extents the binding of the mAbs LIBS1, LIBS6, and PMI-1 to wild
type ␣IIb␤3 (Fig. 5), consistent with the ability of the DTT to
partially activate the receptor. Activation with Mn2⫹ and RGD
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FIG. 4. Expression and ligand binding activity of mutant ␣IIb␤3 integrins
on CHO-K1 transfectants. A, immunofluorescent staining. Staining of specific
transfectants (thick lines) is compared
with mock transfectants (thin lines). B
and C, soluble fibrinogen (B) and PAC-1
mAb (C) binding. Cells were incubated
with ligands in the presence of 5 mM
Ca2⫹, 1 mM Ca2⫹ plus 10 g/ml PT25-2
mAb, 5 mM Ca2⫹ plus 5 mM DTT, or 1 mM
Ca2⫹ plus 10 g/ml PT25-2 and 5 mM DTT
at room temperature for 30 min. Binding
was determined as described under “Materials and Methods” as mean fluorescence intensity. D, adhesion of CHO
transfectants in the presence of 5 mM
Ca2⫹ or 5 mM DTT plus 5 mM Ca2⫹ to
surfaces coated with fibrinogen at the indicated concentrations. Binding of fluorescently labeled transfectants was determined as described under “Materials and
Methods.” Data are representative of
three independent experiments, each in
quadruplicate. S.D. values were on average 1.3% and always less than 4.6%.

peptide resulted in maximal exposure of LIBS epitopes, with or
without DTT treatment. By contrast, LIBS exposure in the low
affinity ␣IIb␤3T329C/A347C mutant was either blunted or absent
in response to RGD plus Mn2⫹ (Fig. 5). This suggests that the
low affinity, disulfide-bonded, mutant receptor is in the overall bent conformation and is largely resistant to Mn2⫹/RGD
activation. DTT treatment of this mutant rescued expression
of LIBS1, LIBS6, and PMI-1 epitopes in response to Mn2⫹
and RGD peptide. For the open mutant ␣IIb␤3V332C/M335C, the
exposure of LIBS1, LIBS6, and PMI-1 epitopes behaved similarly to wild type. The LIBS mAbs bound poorly to the
mutant in Ca2⫹, but Mn2⫹/RGD fully exposed the epitopes.
Therefore, the high affinity mutant is in an overall bent
conformation. These findings suggest that the high affinity
ligand binding of mutant ␣IIb␤3V332C/M335C is due to local
conformational change within the I-like domain. Other LIBS
mAbs including D3 (anti-␤3, residues 422– 490) and AP5 (anti-␤3, residues 1– 6) gave similar results (data not shown).
DISCUSSION

We have tested the hypothesis that axial displacement of the
C-terminal, ␣7-helix of the I-like domain in integrin ␤ subunits
regulates affinity for ligand by a mechanism analogous to that
previously demonstrated for I domains in integrin ␣ subunits.
As reviewed in the Introduction, there is controversy as to
whether the position of the ␣7-helix visualized in crystal struc-

tures corresponds to a low or high affinity conformation and
whether the position of the ␣7-helix moves during conformational regulation of affinity. We present two independent tests
of the hypothesis that the conformation of the ␣7-helix seen in
crystal structures stabilizes integrins in a low affinity conformation and that the helix is displaced during activation: 1) a
disulfide designed to lock the ␣7-helix in the same position as
in crystal structures should stabilize the low affinity state; 2) a
disulfide designed to displace the ␤6-␣7 loop in the C-terminal,
axial direction should activate the high affinity state. Both
experimental tests support the hypothesis, with the first test
providing particularly strong support because the functional
effects of disulfide formation were reversible upon reduction,
and a crystal structure rather than a hypothetical model was
available for designing where the cysteines were introduced.
The formation of each of the introduced disulfide bonds,
Cys329–Cys347 to stabilize the low affinity conformation and
Cys332–Cys335 to stabilize the high affinity conformation, was
directly demonstrated by a shift in mobility in nonreducing
SDS-PAGE and by quantitating free sulfhydryls with biotinylation. An interesting sidelight is that we find a background
level of ⬃0.3 free sulfhydryls per ␤3 subunit in the mature
␣IIb␤3 complex labeled under native conditions. This might
appear to contradict a recent report that resting and activated
conformers of ␣IIb␤3 isolated from outdated human platelets
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FIG. 5. Exposure of LIBS epitopes. Wild-type and mutant CHO
transfectants were incubated in the presence of 5 mM Ca2⫹, 1 mM Mn2⫹
plus 100 M GRGDSP (RGD) peptide, 5 mM DTT plus 5 mM Ca2⫹, or 5
mM DTT plus 1 mM Mn2⫹ and 100 M GRGDSP (RGD) peptide for 30
min at room temperature and then with mAbs on ice for 30 min.
Binding was determined with FITC anti-IgG as described under “Materials and Methods.”

contain 2.6 and 4.4 free cysteines per ␤3 subunit labeled under
denaturing conditions, respectively, and that disulfide exchange is involved in integrin activation (25). However, early
studies on ␣IIb␤3 either isolated from platelets and labeled
under denaturing conditions or labeled with sulfhydryl reagents under native conditions on intact platelets found no free
sulfhydryls in the ␣IIb or ␤3 subunits, whereas the one free
sulfhydryl in the cytoplasmic domain of platelet GpIb was
detected (26, 27). Therefore, our results are in good agreement
with the earlier studies.
The disulfide formed in the ␤3T329C/A347C mutant stabilized
the low affinity state of ␣IIb␤3. Thr329 and Ala347 are located
within the beginning portion of the ␤6-strand and within the
last portion of the ␣7-helix, respectively, much closer to the
“bottom” of the I-like domain that connects to the hybrid domain than to the “top” of the I-like domain that binds ligand.
There is no significant difference in the positions of these
residues between the unliganded and liganded ␣V␤3 crystal
structures (5, 6), and their positions are such that when substituted with cysteine, disulfide bond formation should result
in little or no local structural rearrangement. The Cys329–
Cys347 disulfide bond locked ␣IIb␤3 in the low affinity conformation, as shown by lack of binding to soluble fibrinogen or
PAC-1 mAb, with or without activation. It was interesting that
␣IIb␤3T329C/A347C was also incapable of mediating adhesion of
transfectants to fibrinogen on substrates, which does not require activation. In this assay, binding to ligand may occur as
a consequence of the high local concentration of ligand, and
ligand binding may drive the shift in the equilibrium from the

low to the high affinity conformation of the receptor.
The ␣IIb␤3T329C/A347C mutant remained in the bent conformation as shown by lack of activation epitope exposure. It was
also largely resistant to activation epitope exposure by RGD
peptide and Mn2⫹. The functional effects of disulfide bond
formation were completely reversible by DTT reduction, with
DTT-treated ␣IIb␤3T329C/A347C behaving identically to DTTtreated wild type ␣IIb␤3. We conclude that in crystal structures
determined to date, the ␤3 I-like domain is in the low affinity
state, and for conversion to the high affinity state, a substantial
movement in the position of the side chain of Ala347 relative to
that of Thr329 is required. The position of Thr329 is largely fixed
by its location within a ␤-strand with numerous backbone
hydrogen bonds to the central I-like domain ␤-sheet, and therefore the data are most consistent with a movement of the
␣7-helix containing Ala347.
Results with the ␣IIb␤3V332C/M335C mutant specifically support a conformational change in the ␤6-␣7 loop as an activation
mechanism. The ␤6-␣7 loops of integrin ␤ I-like and ␣ I domains have a different number of residues, and it is therefore
difficult to model rearrangement of the I-like ␤6-␣7 loop. It is
also not clear whether downward movement of the ␣7-helix in
␤ I-like domains would involve one or two turn displacements
as found in the intermediate and open conformations of I domains, respectively (16). Therefore, it is difficult to know
whether the change in the ␤6-␣7 loop induced by disulfide
formation between Cys332 and Cys335 will accurately mimic
physiologic rearrangement of this loop. Nonetheless, the position of residue 332 is largely fixed by its position in the ␤6strand and the backbone hydrogen bonds between the ␤5 and
␤6 strands. Therefore, the backbone rearrangement required to
form the Cys332-Cys335 disulfide bond is almost certain to come
from a downward displacement of the ␤6-␣7 loop, bringing
Cys335 into position to form the disulfide bond with Cys332 that
was directly demonstrated here by chemical labeling studies.
The ␣IIb␤3V332/M335C mutant was constitutively active in soluble ligand binding assays and appeared to be maximally activated. The mutant was also highly active in adhesion to fibrinogen. The activity of the ␣IIb␤3V332C/M335C mutant was not
reversed by reduction. It is likely that the Cys332-Cys335 disulfide bond is resistant to reduction, like most wild type ␤3
disulfides; however, we cannot rule out the possibility that both
the disulfide bond and the combination of two free cysteines at
positions 332 and 335 are activating, although each single
cysteine is not. A converse result was obtained in a similar
study on ␣L I domains; a disulfide designed to stabilize the high
affinity conformation was reversible by DTT, whereas a disulfide designed to stabilize the low affinity conformation was not
reversible with DTT (13, 14, 17).
The high affinity ␣IIb␤3V332C/M335C mutant did not constitutively express activation epitopes, but these were induced upon
treatment with RGD peptide and Mn2⫹. An analogous result
was obtained with an ␣L I domain locked in the high affinity
state with a disulfide bond (14). Subsequent crystal structure
studies on the isolated, high affinity ␣L I domain demonstrated
that the C-terminal ␣7-helix had indeed been displaced downward by the disulfide bond introduced into the ␤6-␣7 loop,
although there was some deformation of the ␣7-helix by the
mutation (16). The intact, high affinity ␣L␤2 heterodimer remained in the bent conformation, and extension was activated
by Mn2⫹, as revealed by mAb to LIBS or activation epitopes.
The interpretation for the ␣L I domains is that the ␣7-helix
should not be viewed as a rigid rod but rather as a spring or a
rope; in other words, some looping out may occur so that a
downward movement of the ␣7-helix in the I domain is not
necessarily transmitted to other integrin domains (14). Simi-
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larly, after introduction here of the Cys332–Cys335 disulfide
between the ␤6-strand and the ␤6-␣7 loop, the local conformational change in this loop did not appear to be transmitted to a
change in orientation between the I-like and hybrid domains,
as revealed by lack of LIBS epitope exposure. This suggests
that the ␣7-helix in the ␤ I-like domain may also behave as a
spring or rope, with conformational change in the ␤6-␣7 loop
not necessarily communicated to downward movement at the
bottom of the ␣7-helix, perhaps because of bulging out of the
␣7-helix or the connection between the ␤6-␣7 loop and the
␣7-helix. Movements of the adjacent ␤ I-like ␣1- and ␣2-helices
have also been implicated in integrin activation (5, 10), and
concerted movements of the ␣1-, ␣2-, and ␣7-helices may be
required for full linkage of the affinity state of the ␤ I-like
MIDAS to the I-like domain interface with the hybrid domain
and explain the ability of RGD peptide plus Mn2⫹ to activate
LIBS epitope exposure in the ␣IIb␤3V332C/M335C mutant.
Taken together, the results with the ␣IIb␤3T329C/A347C and
␣IIb␤3V332C/M335C mutations strongly support the importance of
␤ I-like domain ␣7-helix movement in integrin affinity regulation. Both hypothesis-driven mutations in the ␤ I-like domain
had the predicted effect. One, designed to displace the ␤6-␣7
loop downward, indeed activated ligand binding. The other,
designed to hold the ␤6-strand and ␣7-helix together near the
end of the ␣7-helix, indeed maintained ␣IIb␤3 in the low affinity
state and demonstrated that this relative arrangement of these
two secondary structure elements, visualized in crystal structures (5, 6), corresponds to the low affinity state. Together, the
results with the two mutations support the hypothesis that
C-terminal ␣7-helix displacement increases affinity for ligand
but do not rule out the possibility that additional movements
are also involved in linking the high affinity state of the ligand
binding site to movements at the I-like domain interface with
the hybrid domain and LIBS epitope exposure.
Integrins are important therapeutic targets in many inflammatory and vascular disorders. The rational design of mutations
that allosterically stabilize high affinity or low affinity conformations of integrins demonstrates marked advances in our understanding of the molecular basis of affinity regulation. This progress also holds out the promise that drugs might be designed
that stabilize the low affinity conformation of integrins, in contrast to the current generation of “ligand-mimetic” integrin antagonists that stabilize the high affinity conformation.
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Note Added in Proof—Deletion of one turn (4 residues) of the ␣7-helix
of the ␤2 and ␤7 I-like domains also activates ligand binding, independent of the position of this deletion in the ␣7-helix. This result further
supports the hypothesis that downward movement of the ␣7-helix activates integrins (Yang, W., Shimaoka, M., Chen, J. F., and Springer, T.
A. (2004) Proc. Natl. Acad. Sci. U. S. A., in press).
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